Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-LIGHT: Antiviral Treatment Relief Strategies in HIV-HBV Co-infection
NCT06338826Phase 2Not yet recruiting
- Sponsor
- ANRS
- Start
- Feb 2025
- Primary completion
- Sep 2027
01
Overview
Phase 2, randomised, open-label trial in human immunodeficiency virus infection (HIV) and hepatitis B (HBV) (3 arms), sponsored by ANRS. Primary endpoint: Proportion of participants with HBV virological failure at 96 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Conditions
human immunodeficiency virus infection (HIV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06338826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06338826.